TGRP — Nanopharmaceutics Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeSmall Cap
- $104.40m
- $103.36m
- $1.48m
Annual income statement for Nanopharmaceutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2016 December 31st | 2017 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | 10-K | 10-K |
| Standards: | USG | USG |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 1.48 | 1.48 |
| Cost of Revenue | ||
| Gross Profit | 0.692 | 0.423 |
| Selling / General / Administrative Expenses | ||
| Total Operating Expenses | 2.39 | 2.71 |
| Operating Profit | -0.911 | -1.23 |
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -0.909 | -1.22 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -0.909 | -1.22 |
| Minority Interest | ||
| Net Income Before Extraordinary Items | ||
| Extraordinary Items | ||
| Net Income | -0.576 | -0.804 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -0.576 | -0.804 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -0.004 | -0.005 |
| Dividends per Share |